Our findings of FOXM1 expression, itself and in combination with FOXO3a, as a potential marker for risk stratification of both childhood and adult, Ph+ ALL provide a robust basis for further, prospective analyses of FOXM1 in clinical trials. This evidence concerns the gene FOXO3 and acute lymphoblastic leukemia.